Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMNL1-overexpressing CAR-T cells
- Development stage
- Preclinical
- Lead developer
- University of Colorado
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
FMNL1-overexpressing CAR-T cells are an engineered adoptive cellular therapy designed to overcome the physical barriers of the solid tumor microenvironment. By overexpressing Formin-like-1 (FMNL1), a key regulator of the actin cytoskeleton and T cell migration, these cells exhibit enhanced motility and infiltration capabilities. This modification allows the T cells to better penetrate dense extracellular matrix and abnormal vasculature, which typically limit the efficacy of standard CAR-T therapies in solid tumors. Preclinical data presented at AACR 2026 demonstrated that these cells significantly increase accumulation at tumor sites and prolong survival in murine models of melanoma and lung carcinoma, regardless of the specific CAR construct or tumor antigen used.
- Other names
- FMNL1-overexpressing chimeric antigen receptor T cellsFMNL-1-overexpressing chimeric antigen receptor T cellsFMNL 1-overexpressing chimeric antigen receptor T cells
Beyond the preview
Go deeper on FMNL1-overexpressing CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMNL1-overexpressing CAR-T cells.